Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment

International Journal of Oncology

Volumn 41, Issue 1, 2012, Pages 15-23

  Lönnroth, Christina ^a   Andersson, Marianne ^a   Nordgren, Svante ^a   Lundholm, Kent ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Colorectal cancer; Indomethacin; Non steroidal anti inflammatory drugs; Prominin 1 CD133

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CELECOXIB; COFORTID; EPITHELIAL CELL ADHESION MOLECULE; ESOMEPRAZOLE; INDOMETACIN; MESSENGER RNA; PROMININ 1; PROSTAGLANDIN E2; PROTEIN; UNCLASSIFIED DRUG; WNT4 PROTEIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; COLORECTAL CARCINOMA; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; POLYMERASE CHAIN REACTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, CD; CARCINOMA; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DINOPROSTONE; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; INDOMETHACIN; MALE; MIDDLE AGED; PEPTIDES; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REAL-TIME POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; SULFONAMIDES; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84862856888     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1460     Document Type: Article

References (51)

1. Lönnroth C, Andersson M, Arvidsson A, Nordgren S, Brevinge H, Lagerstedt K and Lundholm K: Preoperative treatment with a non-steroidal antiinflammaatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun 8: 5, 2008.
2. 2. Int J Oncol 36: 469-478, 2010.
3. Auman JT, Church R, Lee SY, Watson MA, Fleshman JW and McLeod HL: Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. Eur J Cancer 44: 1754-1760, 2008.
4. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK and Buck DW: A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90: 5013-5021, 1997. (Pubitemid 28007218)
5. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J and Buck DW: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012, 1997. (Pubitemid 28007217)
6. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C and De Maria R: Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115, 2007. (Pubitemid 46067311)
7. - metastatic colon cancer cells initiate tumors. J Clin Invest 118: 2111-2120, 2008.
8. Horst D, Kriegl L, Engel J, Kirchner T and Jung A: CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99: 1285-1289, 2008.
9. Ong CW, Kim LG, Kong HH, Low LY, Iacopetta B, Soong R and Salto-Tellez M: CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol 23: 450-457, 2010.
10. Nakamura M, Kyo S, Zhang B, Zhang X, Mizumoto Y, Takakura M, Maida Y, Mori N, Hashimoto M, Ohno S and Inoue M: Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. Hum Pathol 41: 1516-1529, 2010.
11. Cahlin C, Lönnroth C, Arvidsson A, Nordgren S and Lundholm K: Growth associated proteins in tumor cells and stroma related to disease progression of colon cancer accounting for tumor tissue PGE2 content. Int J Oncol 32: 909-918, 2008. (Pubitemid 351780601)
12. Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, Svaninger G, Korner U, Gulich M, Karrefors I, Norli B, Hafström L, Kewenter J, Olbe L and Lundell L: Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54: 5602-5606, 1994.
13. Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Wang W, Lonnroth C and Lundholm K: EP1-4 subtype, COX and PPARgamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer 121: 232-240, 2007. (Pubitemid 46917690)
14. Forslund A, Engaras B, Lonnroth C and Lundholm K: Prediction of postoperative survival by preoperative serum concentrations of anti-p53 compared to CEA, CA 50, CA 242 and conventional blood tests in patients with colorectal carcinoma. Int J Oncol 20: 1013-1018, 2002.
15. Lin EH, Hassan M, Li Y, Zhao H, Nooka A, Sorenson E, Xie K, Champlin R, Wu X and Li D: Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer 110: 534-542, 2007. (Pubitemid 47106141)
16. Mutter GL, Zahrieh D, Liu C, Neuberg D, Finkelstein D, Baker HE and Warrington JA: Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays. BMC Genomics 5: 88, 2004.
17. Rabascio C, Muratori E, Mancuso P, Calleri A, Raia V, Foutz T, Cinieri S, Veronesi G, Pruneri G, Lampertico P, Iavarone M, Martinelli G, Goldhirsch A and Bertolini F: Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res 64: 4373-4377, 2004. (Pubitemid 38802446)
18. Schwartzbaum JA, Huang K, Lawler S, Ding B, Yu J and Chiocca EA: Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. Neuro Oncol 12: 320-327, 2010.
19. Deng Y, Wang L, Taian Q, Miller C, Lin T, Chien AJ, Ulrich CM, Grady WM, Blau CA and Lin EH: Regulation of expression of CD133, a colon cancer stem cell marker and other stemness genes/pathways, by celecoxib: Clues from clinical observations. J Clin Oncol 27 (suppl) abst 15065, 2009.
20. Mizrak D, Brittan M and Alison MR: CD133: molecule of the moment. J Pathol 214: 3-9, 2008.
21. Corbeil D, Roper K, Hellwig A, Tavian M, Miraglia S, Watt SM, Simmons PJ, Peault B, Buck DW and Huttner WB: The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 275: 5512-5520, 2000. (Pubitemid 30115186)
22. Jaszai J, Fargeas CA, Florek M, Huttner WB and Corbeil D: Focus on molecules: prominin-1 (CD133). Exp Eye Res 85: 585-586, 2007. (Pubitemid 350001359)
23. Fargeas CA, Corbeil D and Huttner WB: AC133 antigen, CD133, prominin-1, prominin-2, etc.: prominin family gene products in need of a rational nomenclature. Stem Cells 21: 506-508, 2003. (Pubitemid 36793492)
24. Roper K, Corbeil D and Huttner WB: Retention of prominin in microvilli reveals distinct cholesterol-based lipid micro-domains in the apical plasma membrane. Nat Cell Biol 2: 582-592, 2000.
25. Giebel B, Corbeil D, Beckmann J, Hohn J, Freund D, Giesen K, Fischer J, Kogler G and Wernet P: Segregation of lipid raft markers including CD133 in polarized human hematopoietic stem and progenitor cells. Blood 104: 2332-2338, 2004. (Pubitemid 39331830)
26. Weigmann A, Corbeil D, Hellwig A and Huttner WB: Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci USA 94: 12425-12430, 1997. (Pubitemid 27492544)
27. Polverini PJ: Angiogenesis in health and disease: insights into basic mechanisms and therapeutic opportunities. J Dent Educ 66: 962-975, 2002.
28. Gupta K and Zhang J: Angiogenesis: a curse or cure? Postgrad Med J 81: 236-242, 2005. (Pubitemid 40546620)
29. Simpson RJ, Jensen SS and Lim JW: Proteomic profiling of exosomes: current perspectives. Proteomics 8: 4083-4099, 2008.
30. Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S and Rivoltini L: Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 15: 80-88, 2008. (Pubitemid 350286175)
31. Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Urbanowicz B, Branski P, Ratajczak MZ and Zembala M: Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother 55: 808-818, 2006.
32. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ and Lotvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654-659, 2007. (Pubitemid 47214727)
33. de Gassart A, Geminard C, Fevrier B, Raposo G and Vidal M: Lipid raft-associated protein sorting in exosomes. Blood 102: 4336-4344, 2003. (Pubitemid 37494093)
34. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A and Rak J: Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 10: 619-624, 2008. (Pubitemid 351627382)
35. Choi DS, Lee JM, Park GW, Lim HW, Bang JY, Kim YK, Kwon KH, Kwon HJ, Kim KP and Gho YS: Proteomic analysis of microvesicles derived from human colorectal cancer cells. J Proteome Res 6: 4646-4655, 2007.
36. Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, Villa A, Corbelli A, Fais S, Parmiani G and Rivoltini L: Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res 66: 9290-9298, 2006. (Pubitemid 44521151)
37. Johnstone RM: Exosomes biological significance: A concise review. Blood Cells Mol Dis 36: 315-321, 2006.
38. Giusti I, D'Ascenzo S, Millimaggi D, Taraboletti G, Carta G, Franceschini N, Pavan A and Dolo V: Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles. Neoplasia 10: 481-488, 2008. (Pubitemid 351657390)
39. Huber V, Fais S, Iero M, Lugini L, Canese P, Squarcina P, Zaccheddu A, Colone M, Arancia G, Gentile M, Seregni E, Valenti R, Ballabio G, Belli F, Leo E, Parmiani G and Rivoltini L: Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 128: 1796-1804, 2005. (Pubitemid 40824690)
40. O'Connor R: Concealed cargo within the tumor microenvironment: microvesicles disseminate oncogenic receptors among cancer cells. Cancer Biol Ther 7: 1350-1351, 2008.
41. Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, Bruno S, Bussolati B and Camussi G: Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 110: 2440-2448, 2007. (Pubitemid 47523165)
42. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A and Ratajczak MZ: Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 20: 1487-1495, 2006. (Pubitemid 44264090)
43. Ernst M, Najdovska M, Grail D, Lundgren-May T, Buchert M, Tye H, Matthews VB, Armes J, Bhathal PS, Hughes NR, Marcusson EG, Karras JG, Na S, Sedgwick JD, Hertzog PJ and Jenkins BJ: STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 118: 1727-1738, 2008. (Pubitemid 351632376)
44. Merchant JL: What lurks beneath: IL-11, via Stat3, promotes inflammation-associated gastric tumorigenesis. J Clin Invest 118: 1628-1631, 2008.
45. Marzesco AM, Janich P, Wilsch-Brauninger M, Dubreuil V, Langenfeld K, Corbeil D and Huttner WB: Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. J Cell Sci 118: 2849-2858, 2005. (Pubitemid 41136362)
46. Florek M, Bauer N, Janich P, Wilsch-Braeuninger M, Fargeas CA, Marzesco AM, Ehninger G, Thiele C, Huttner WB and Corbeil D: Prominin-2 is a cholesterol-binding protein associated with apical and basolateral plasmalemmal protrusions in polarized epithelial cells and released into urine. Cell Tissue Res 328: 31-47, 2007. (Pubitemid 46411908)
47. Lönnroth C, Andersson M and Lundholm K: Indomethacin and telomerase activity in tumor growth retardation. Int J Oncol 18: 929-937, 2001.
48. Grau MV, Rees JR and Baron JA: Chemoprevention in gastrointestinal cancers: current status. Basic Clin Pharmacol Toxicol 98: 281-287, 2006.
49. Wang D and Dubois RN: Prostaglandins and cancer. Gut 55: 115-122, 2006. (Pubitemid 41820645)
50. Lönnroth C, Svaninger G, Gelin J, Cahlin C, Iresjö B, Cvetkovska E, Edström S, Andersson M, Svanberg E and Lundholm K: Effects related to indomethacin prolonged survival and decreased tumor growth in a mouse tumor model with cytokine dependent cancer cachexia. Int J Oncol 7: 1405-1413, 1995.
51. Axelsson H, Lönnroth C, Andersson M, Wang W and Lundholm K: Global tumor RNA expression in early establishment of experimental tumor growth and related angiogenesis following COX-inhibition evaluated by microarray analysis. Cancer Inform 3: 125-139, 2007.